Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP NASDAQ:HUMA NASDAQ:PBYI NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$13.01+4.7%$11.68$2.31▼$14.70$59.92M-0.5743,875 shs32,982 shsHUMAHumacyte$1.47-2.0%$2.00$1.15▼$6.77$237.56M1.873.36 million shs1.17 million shsPBYIPuma Biotechnology$4.47-0.7%$4.19$2.32▼$6.07$226.67M1.38665,169 shs377,459 shsPRQRProQR Therapeutics$2.19$2.21$1.07▼$4.62$230.42M0.36346,714 shs472,345 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics+4.67%+6.03%+19.80%+55.62%+251.81%HUMAHumacyte-2.00%+2.80%-17.42%-37.97%-74.17%PBYIPuma Biotechnology-0.67%-11.13%-15.66%+33.43%+78.80%PRQRProQR Therapeutics0.00%-10.61%+8.42%+16.49%+18.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$13.01+4.7%$11.68$2.31▼$14.70$59.92M-0.5743,875 shs32,982 shsHUMAHumacyte$1.47-2.0%$2.00$1.15▼$6.77$237.56M1.873.36 million shs1.17 million shsPBYIPuma Biotechnology$4.47-0.7%$4.19$2.32▼$6.07$226.67M1.38665,169 shs377,459 shsPRQRProQR Therapeutics$2.19$2.21$1.07▼$4.62$230.42M0.36346,714 shs472,345 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics+4.67%+6.03%+19.80%+55.62%+251.81%HUMAHumacyte-2.00%+2.80%-17.42%-37.97%-74.17%PBYIPuma Biotechnology-0.67%-11.13%-15.66%+33.43%+78.80%PRQRProQR Therapeutics0.00%-10.61%+8.42%+16.49%+18.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 0.00N/AN/AN/AHUMAHumacyte 2.88Moderate Buy$9.75563.27% UpsidePBYIPuma Biotechnology 3.00Buy$7.0056.60% UpsidePRQRProQR Therapeutics 3.13Buy$8.00265.30% UpsideCurrent Analyst Ratings BreakdownLatest COEP, PRQR, HUMA, and PBYI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/27/2025HUMAHumacyteBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.508/12/2025HUMAHumacyteTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $3.508/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/11/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/8/2025PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.007/23/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/11/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/27/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$8.006/27/2025PRQRProQR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/AHUMAHumacyte$1.57M148.28N/AN/A($0.41) per share-3.59PBYIPuma Biotechnology$230.50M0.98$0.85 per share5.28$1.88 per share2.38PRQRProQR Therapeutics$16.49M13.98N/AN/A$0.91 per share2.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-201.73%-108.46%N/AHUMAHumacyte-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)PBYIPuma Biotechnology$30.28M$0.984.5611.76N/A20.38%53.15%23.51%11/6/2025 (Estimated)PRQRProQR Therapeutics-$30.04M-$0.46N/AN/AN/A-238.52%-61.25%-28.13%11/6/2025 (Estimated)Latest COEP, PRQR, HUMA, and PBYI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COEPCoeptis TherapeuticsN/A-$1.17N/A-$1.17N/A$0.20 million8/11/2025Q2 2025HUMAHumacyte-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 million8/7/2025Q2 2025PRQRProQR Therapeutics-$0.08-$0.14-$0.06-$0.14$5.01 million$4.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.830.83HUMAHumacyte2.972.451.93PBYIPuma Biotechnology0.101.731.62PRQRProQR TherapeuticsN/A3.763.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%HUMAHumacyte44.71%PBYIPuma Biotechnology61.29%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%HUMAHumacyte5.10%PBYIPuma Biotechnology23.30%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics24.82 million3.65 millionNot OptionableHUMAHumacyte150158.37 million150.30 millionOptionablePBYIPuma Biotechnology20050.37 million38.64 millionOptionablePRQRProQR Therapeutics180105.21 million96.38 millionOptionableCOEP, PRQR, HUMA, and PBYI HeadlinesRecent News About These CompaniesProQR Therapeutics N.V. $PRQR Shares Sold by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.comHC Wainwright Expects Lower Earnings for ProQR TherapeuticsAugust 30, 2025 | marketbeat.comProQR Therapeutics N.V. $PRQR Shares Bought by Affinity Asset Advisors LLCAugust 28, 2025 | marketbeat.com1,850,348 Shares in ProQR Therapeutics N.V. $PRQR Purchased by Aberdeen Group plcAugust 24, 2025 | marketbeat.comProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by BrokeragesAugust 20, 2025 | marketbeat.comPRQR | ProQR Therapeutics N.V. Stock Price & News - WSJAugust 12, 2025 | wsj.comProQR Announces Second Quarter 2025 Operating and Financial ResultsAugust 7, 2025 | globenewswire.comProQR Announces Upcoming Presentation at RNA Editing SummitJuly 28, 2025 | globenewswire.comProQR Therapeutics price target raised to $5 from $4 at Evercore ISIJuly 12, 2025 | msn.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.comJuly 8, 2025 | investing.comPRQR - ProQR Therapeutics NV Sustainability - MorningstarJuly 3, 2025 | morningstar.comMPRQR - ProQR Therapeutics NV Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMProQR Therapeutics NV (PRQR) Stock Forums - Investing.comJune 29, 2025 | investing.comProQR Therapeutics N.V. (PRQR) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 27, 2025 | finanznachrichten.deProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 26, 2025 | globenewswire.comProQR Therapeutics Reports Q1 2025 Financial ResultsJune 2, 2025 | tipranks.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal yearMay 24, 2025 | investing.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesMay 12, 2025 | globenewswire.comProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial PositionMay 10, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOEP, PRQR, HUMA, and PBYI Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$13.01 +0.58 (+4.67%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$13.20 +0.20 (+1.50%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.Humacyte NASDAQ:HUMA$1.47 -0.03 (-2.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.48 +0.01 (+0.68%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Puma Biotechnology NASDAQ:PBYI$4.47 -0.03 (-0.67%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.47 0.00 (0.00%) As of 09/12/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.ProQR Therapeutics NASDAQ:PRQR$2.19 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.18 0.00 (-0.23%) As of 09/12/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
